CNOT10 Antibody

What is CNOT10 and why is it significant for cellular research?

CNOT10 is a critical subunit of the CCR4-NOT complex, which plays an essential role in regulating gene expression and mRNA degradation in eukaryotic cells. The CCR4-NOT complex consists of multiple CNOT subunits (including CNOT10) and TAB182, functioning collectively to maintain cellular homeostasis . The significance of CNOT10 extends beyond its structural role in the complex to include regulation of histone modifications, particularly influencing methylation of histone H3 at lysine 4 through a ubiquitin-dependent pathway . This epigenetic regulatory function allows CNOT10 to alter chromatin structure and gene accessibility, thereby impacting transcriptional regulation and cellular responses to various stimuli. The complex's function as a transcriptional regulator and repressor of nuclear receptor signaling makes it particularly relevant in cancer research, where dysregulation of these pathways can contribute to tumorigenesis .

What types of CNOT10 antibodies are available for research applications?

Several types of CNOT10 antibodies are available for research, each with distinct characteristics suitable for different experimental approaches:

• Monoclonal antibodies: CNOT10 Antibody (H-9) is a mouse monoclonal IgG1 kappa light chain antibody that detects CNOT10 protein from mouse, rat, and human origins . This antibody is available in both non-conjugated form and various conjugated forms including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates .

• Polyclonal antibodies: CNOT10 Rabbit Polyclonal antibody is produced by immunization with CNOT10 recombinant protein (Accession Number: NM_001256741) and purified using antigen affinity methods . This antibody demonstrates reactivity with human CNOT10 and has been validated in multiple tissues and cell lines .

The choice between monoclonal and polyclonal antibodies should be guided by specific experimental requirements. Monoclonal antibodies offer high specificity for a single epitope, resulting in consistent lot-to-lot reproducibility. Polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals but with possible batch variation.

What are the validated applications for CNOT10 antibodies?

CNOT10 antibodies have been validated for multiple research applications, with successful results in various experimental contexts:

The rabbit polyclonal antibody has been positively validated in various sample types, including:

• Western blotting: Human brain tissue, human testis tissue

• Immunohistochemistry: Human colon cancer tissue

• Immunofluorescence: HepG2 cells

• Immunoprecipitation: Mouse brain tissue

The mouse monoclonal H-9 antibody has demonstrated multi-species reactivity (mouse, rat, and human), making it suitable for comparative studies across these species .

How does CNOT10 function within the CCR4-NOT complex architecture?

CNOT10 functions as part of a modular architecture within the CCR4-NOT complex, which comprises at least three distinct functional modules:

• The CCR4-CAF1 deadenylase module: Responsible for the complex's deadenylase activity

• The NOT module: Involved in various aspects of transcriptional regulation

• The CNOT10/CNOT11 module: A protein-protein interaction platform that interacts with the N-terminal part of CNOT1

CNOT10 specifically partners with CNOT11 (formerly known as C2ORF29) to form the CNOT10/CNOT11 module. This module is essential for the structural integrity and function of the CCR4-NOT complex . The CNOT10/CNOT11 module interacts with the first amino acids of CNOT1, the largest scaffolding protein in the complex, and CNOT11 is required for the association of CNOT10 with the CCR4-NOT complex .

This modular organization is evolutionarily significant, as phylogenetic analyses indicate that while the CNOT10/CNOT11 module is conserved in most eukaryotes, it is absent in fungi . This suggests a specialized function for this module that may have evolved in higher organisms.

How should researchers design co-immunoprecipitation experiments using CNOT10 antibodies?

When designing co-immunoprecipitation (Co-IP) experiments to study CNOT10 interactions, researchers should consider the following methodological aspects:

• Antibody selection: Use IP-validated antibodies. Both the mouse monoclonal (H-9) and rabbit polyclonal CNOT10 antibodies have been validated for IP applications . For the rabbit polyclonal antibody, the recommended dilution for IP is 1:200-1:1000 .

• Lysate preparation:

  • Use gentle lysis buffers containing 20-50 mM Tris-HCl (pH 7.4-8.0), 100-150 mM NaCl, 1-5 mM EDTA, and 0.5-1% NP-40 or Triton X-100.

  • Include protease inhibitors to prevent protein degradation.

  • For studying CNOT10's interactions with nuclear proteins, consider nuclear extract preparation methods.

• Pre-clearing: Pre-clear lysates with appropriate control IgG and protein A/G beads to reduce non-specific binding.

• Immunoprecipitation:

  • For agarose-conjugated antibodies: Directly incubate pre-cleared lysate with CNOT10 antibody-conjugated agarose beads.

  • For non-conjugated antibodies: Incubate lysate with CNOT10 antibody first, then add protein A/G beads.

• Controls: Include appropriate controls:

  • IgG control (same species as the CNOT10 antibody)

  • Input sample (5-10% of initial lysate)

  • If studying specific interactions, consider knockdown/knockout controls

• Optimizations: When studying specific CNOT10 interactions, particularly with CNOT11 or other CCR4-NOT complex components, mild crosslinking (0.1-0.5% formaldehyde) before lysis may help preserve weak or transient interactions.

• Analysis: Analyze immunoprecipitated complexes by western blotting using antibodies against expected interaction partners. For the CNOT10/CNOT11 module, this would include antibodies against CNOT1 (particularly its N-terminal region) and CNOT11 .

Successful IP of CNOT10 has been demonstrated in mouse brain tissue using the rabbit polyclonal antibody at a dilution of 1:300 for detection .

What are the optimal conditions for immunofluorescence detection of CNOT10?

For optimal immunofluorescence (IF) detection of CNOT10, consider the following protocol recommendations:

• Fixation and permeabilization:

  • Fix cells with 4% paraformaldehyde (10-15 minutes at room temperature)

  • Permeabilize with 0.1-0.5% Triton X-100 in PBS (5-10 minutes)

  • For nuclear protein detection, ensure adequate nuclear permeabilization

• Blocking:

  • Block with 1-5% BSA or 5-10% normal serum (from the species of secondary antibody) in PBS

  • Include 0.1-0.3% Triton X-100 in blocking buffer to enhance antibody penetration

  • Block for 30-60 minutes at room temperature

• Primary antibody incubation:

  • For rabbit polyclonal CNOT10 antibody: Use at 1:10-1:100 dilution

  • For mouse monoclonal (H-9): Follow manufacturer's recommendations

  • Incubate overnight at 4°C or 1-2 hours at room temperature

  • Dilute antibody in blocking buffer

• Washing: Wash 3-5 times with PBS containing 0.1% Tween-20

• Secondary antibody incubation:

  • Use fluorophore-conjugated secondary antibodies specific to the primary antibody species

  • For example, with rabbit polyclonal CNOT10 antibody, use Rhodamine-labeled goat anti-rabbit IgG as validated in HepG2 cells

  • Incubate for 1-2 hours at room temperature

  • Protect from light during and after secondary antibody incubation

• Nuclear counterstaining: Use DAPI or Hoechst (1-5 μg/ml) for 5-10 minutes

• Mounting: Mount with anti-fade mounting medium to preserve fluorescence

• Controls:

  • Include a secondary-only control

  • Consider CNOT10 knockdown/knockout cells as negative controls

  • Include positive controls (cells known to express CNOT10)

Successful IF detection of CNOT10 has been demonstrated in HepG2 cells using the rabbit polyclonal antibody at 1:25 dilution with Rhodamine-labeled goat anti-rabbit IgG as the secondary antibody .

How is the CNOT10/CNOT11 module involved in ribosome recognition and translational regulation?

The CNOT10/CNOT11 module plays a critical role in ribosome recognition and translational regulation through several mechanisms:

• Direct interaction with ribosomes: The CNOT10/CNOT11 module has been shown to crosslink with specific ribosomal proteins, including uS5, eS19, eS31, and eL29, establishing its direct physical interaction with ribosomes, particularly with the 40S ribosomal subunit . This positioning places the CNOT10/CNOT11 module in close spatial proximity to the translational machinery.

• Stalled ribosome recognition: The CCR4-NOT complex, potentially through the CNOT10/CNOT11 module, participates in the recognition of stalled ribosomes. This recognition is part of a quality control mechanism that targets aberrant translation events .

• Protein-protein interaction platform: The CNOT10/CNOT11 module functions as a protein-protein interaction platform within the CCR4-NOT complex . This role allows it to mediate interactions between the complex and other molecular machinery, including ribosomes and potentially factors involved in translation regulation.

• Association with ubiquitination pathways: The CNOT1 N-terminus, which interacts with the CNOT10/CNOT11 module, has been observed to crosslink with ubiquitin, potentially attached to ribosomal protein eS7 . This suggests that the CNOT10/CNOT11 module may be involved in ribosome-associated ubiquitination events, which are known to play roles in ribosome-associated quality control.

• Structural platform for the CCR4-NOT complex: As an integral part of the CCR4-NOT complex, the CNOT10/CNOT11 module contributes to the structural organization that allows the complex to engage with translating ribosomes. This positioning is crucial for the complex's functions in mRNA decay and translational repression .

Understanding the CNOT10/CNOT11 module's role in ribosome recognition provides insights into how the CCR4-NOT complex coordinates mRNA degradation with translation, ensuring proper gene expression regulation and mRNA quality control.

What is the role of CNOT10 in immune sensing pathways and double-stranded RNA recognition?

Recent research has uncovered a significant role for CNOT10 in immune sensing pathways, particularly in the context of double-stranded RNA (dsRNA) recognition:

• Complex formation with GGNBP2 and CNOT11: CNOT10 interacts with GGNBP2 and CNOT11 to form a functional complex that regulates the sensing of unedited cellular dsRNA . This interaction represents a previously undescribed pathway in the cellular response to immunogenic self dsRNA.

• MDA5 sensing regulation: The GGNBP2-CNOT10-CNOT11 complex specifically regulates MDA5 sensing triggered by self dsRNA . MDA5 (melanoma differentiation-associated protein 5) is a pattern recognition receptor that detects viral and self dsRNA in the cytoplasm, triggering type I interferon responses.

• Cytoplasmic dsRNA accumulation: The complex is required for the cytoplasmic accumulation of unedited dsRNA, which is subsequently sensed by MDA5 . This suggests that CNOT10, together with its partners, facilitates the localization and/or stability of immunogenic self dsRNA.

• Relevance to ADAR mutations: This pathway appears to be particularly relevant in the context of ADAR (Adenosine Deaminase Acting on RNA) mutations . ADAR enzymes edit double-stranded RNA by converting adenosine to inosine, thereby preventing immune activation by self dsRNA. In ADAR-deficient contexts, the GGNBP2-CNOT10-CNOT11 complex likely becomes critical in regulating the resulting enhanced immune responses.

• Potential therapeutic implications: Understanding this pathway may have implications for ADAR1 inhibitor development and use, as it could influence response or resistance to such inhibitors .

This discovery expands our understanding of CNOT10 beyond its canonical role in the CCR4-NOT complex and mRNA degradation, highlighting its function in innate immune regulation. For researchers studying autoimmune diseases, particularly those with a type I interferon signature, targeting or modulating the GGNBP2-CNOT10-CNOT11 complex could represent a novel therapeutic approach.

How can researchers investigate CNOT10's role in histone modification and epigenetic regulation?

To investigate CNOT10's role in histone modification and epigenetic regulation, researchers should consider these methodological approaches:

• Chromatin Immunoprecipitation (ChIP) studies:

  • Use CNOT10 antibodies to perform ChIP followed by sequencing (ChIP-seq) to identify genomic regions where CNOT10 binds.

  • Compare CNOT10 binding sites with histone modification patterns, particularly H3K4 methylation, which CNOT10 is known to influence .

  • For ChIP applications, use formaldehyde crosslinking (1%, 10 minutes at room temperature) to preserve protein-DNA interactions.

  • Sequential ChIP (Re-ChIP) can be employed to identify regions where CNOT10 co-localizes with specific histone marks or other CCR4-NOT components.

• Histone modification analysis:

  • Perform western blotting for H3K4 methylation (mono-, di-, and trimethylation) in CNOT10 knockdown/knockout cells.

  • Use immunofluorescence to visualize changes in H3K4 methylation patterns upon CNOT10 manipulation.

  • Mass spectrometry-based approaches can provide quantitative analysis of histone modifications in the presence or absence of functional CNOT10.

• Functional ubiquitination studies:

  • Investigate the ubiquitin-dependent pathway through which CNOT10 influences H3K4 methylation .

  • Use proteasome inhibitors (e.g., MG132) to determine if the effect is proteasome-dependent.

  • Perform ubiquitination assays using tagged ubiquitin constructs to identify specific histone or histone-modifying enzymes targeted by CNOT10-mediated ubiquitination.

• Transcriptomic and epigenomic profiling:

  • RNA-seq analysis of CNOT10-depleted cells can identify genes whose expression is affected by CNOT10.

  • ATAC-seq can reveal changes in chromatin accessibility resulting from altered histone modifications.

  • Integration of these datasets with ChIP-seq data can provide a comprehensive view of CNOT10's epigenetic regulatory function.

• Protein interaction studies:

  • Use CNOT10 antibodies for co-immunoprecipitation followed by mass spectrometry to identify interactions with histone-modifying enzymes.

  • Proximity ligation assays can visualize interactions between CNOT10 and specific histone marks or modifying enzymes in situ.

• Cancer model systems:

  • Given CNOT10's relevance in cancer contexts , use cancer cell lines or patient-derived samples to investigate how CNOT10-mediated epigenetic regulation contributes to tumorigenesis.

  • Compare CNOT10 expression, localization, and associated histone modifications between normal and cancer tissues.

By employing these approaches, researchers can elucidate the mechanisms by which CNOT10 influences chromatin structure and gene accessibility, contributing to our understanding of epigenetic regulation in normal and disease states.

What are the critical considerations for using CNOT10 antibodies in cancer research models?

When employing CNOT10 antibodies in cancer research models, researchers should carefully consider these critical factors:

• Antibody validation in specific cancer contexts:

  • Validate antibody specificity in each cancer model system through western blotting, comparing with CNOT10 knockdown/knockout controls.

  • The rabbit polyclonal CNOT10 antibody has been validated in human colon cancer tissue using immunohistochemistry , making it potentially suitable for colorectal cancer studies.

  • For novel cancer models, preliminary validation should include both positive controls (known CNOT10-expressing tissues) and negative controls.

• Expression heterogeneity assessment:

  • Use immunohistochemistry with CNOT10 antibodies (recommended dilution 1:20-1:200 for rabbit polyclonal ) to evaluate expression heterogeneity across tumor samples.

  • Consider tissue microarray approaches for high-throughput screening of CNOT10 expression across multiple tumor samples.

  • Correlate CNOT10 expression patterns with clinicopathological features to identify potential prognostic associations.

• Subcellular localization analysis:

  • Use immunofluorescence with CNOT10 antibodies to determine subcellular localization, which may be altered in cancer cells.

  • Perform nuclear-cytoplasmic fractionation followed by western blotting to quantify compartment-specific CNOT10 expression changes.

  • Co-staining with markers for specific cellular compartments can provide insights into CNOT10's functional redistribution in cancer cells.

• Complex integrity assessment:

  • Use co-immunoprecipitation with CNOT10 antibodies to evaluate whether the integrity of the CCR4-NOT complex is maintained in cancer cells.

  • Focus particularly on the CNOT10-CNOT11 module and its interaction with CNOT1, as these may be dysregulated in cancer .

• Functional studies in cancer models:

  • When studying CNOT10's role in transcriptional regulation and repression of nuclear receptor signaling (relevant to cancer contexts ), use ChIP with CNOT10 antibodies to identify cancer-specific binding sites.

  • Investigate CNOT10's involvement in histone modifications, especially H3K4 methylation, which may be altered in cancer.

• Technical considerations for different cancer models:

  • For fixed tissue samples: Antigen retrieval methods may need optimization for IHC applications, as fixation can mask epitopes.

  • For cell lines: Consider cell-specific expression levels when determining optimal antibody dilutions.

  • For patient-derived xenografts: Confirm species specificity of the antibody to distinguish host from tumor signals.

• Integration with immune signaling studies:

  • Given CNOT10's role in immune sensing pathways , consider investigating its function in cancer immune evasion mechanisms.

  • Use CNOT10 antibodies in combination with markers for tumor-infiltrating immune cells to explore potential correlations.

By addressing these considerations, researchers can effectively employ CNOT10 antibodies to advance our understanding of how this protein contributes to cancer development, progression, and potential therapeutic vulnerabilities.

Future Directions in CNOT10 Antibody Research Applications

The emerging roles of CNOT10 in diverse cellular processes present exciting opportunities for future research applications of CNOT10 antibodies. As our understanding of the CCR4-NOT complex continues to evolve, CNOT10 antibodies will remain essential tools for studying:

• The structural organization and dynamic remodeling of the CCR4-NOT complex in different cellular contexts and disease states.

• The CNOT10/CNOT11 module's function as a protein-protein interaction platform and its role in ribosome recognition.

• The involvement of CNOT10 in immune sensing pathways, particularly in the context of autoimmune diseases and cancer immunotherapy.

• The epigenetic regulatory functions of CNOT10 and their implications for gene expression programs in development and disease.

• The potential of CNOT10 as a diagnostic marker or therapeutic target in cancers where CCR4-NOT complex dysregulation contributes to pathogenesis.